Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385989288> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4385989288 endingPage "iii39" @default.
- W4385989288 startingPage "iii39" @default.
- W4385989288 abstract "Abstract BACKGROUND Despite progress in the treatment of brain metastasis (BrM) for HER2+ breast cancer (BC), outcomes for patients with HER2-negative BC BrM remain poor. Current standard of care consists of surgery and/or radiotherapy followed by systemic therapy. Preclinical studies show inhibitors of poly(ADP-ribose) polymerase (PARP) are effective together with radiotherapy as DNA damage response inhibitors. Triple-negative BC (TNBC) has higher rates of homologous recombination deficiency compared to other BC subtypes, and together with HER2-negative, BRCA-mutated BC would be particularly sensitive to PARP inhibition. PARP inhibition with immunotherapy has demonstrated promising efficacy in patients with germline BRCA-mutant and metastatic TNBC in clinical trials (MEDIOLA, TOPACIO). In addition, immunotherapy with stereotactic radiosurgery (SRS) is associated with favorable outcomes in patients with BrM. We hypothesize that this biologically-driven combination will enhance local control of SRS-treated BrM through synergy with PARP inhibition, while controlling micrometastatic disease in the brain and extracranial sites by potentiating the immune response. METHODS We are conducting a multi-institution, Phase I/II trial of SRS plus olaparib, followed by durvalumab (with physician’s choice systemic therapy), for patients with TNBC (any BRCA status) or HER2-negative with BRCA-mutated (germline or somatic) BC BrM [NCT04711824]. The primary objectives are to evaluate safety and tolerability (Phase I) and intracranial disease control at 6 months (Phase II). Secondary objectives include assessing intracranial and global progression-free survival, overall survival, and intracranial/extracranial response rate. Exploratory objectives will assess potential biomarkers of treatment response, including changes in circulating tumor cells/DNA in blood and cerebrospinal fluid, germline and tumor mutations in DNA repair pathway genes, and PD-L1 expression, as well as quality of life and patient-reported outcomes. A surgical sub-study (n=5) will evaluate olaparib concentration/distribution in resected BrM. As of January 2023, cohort 1 of phase I has been completed without dose-limiting toxicity." @default.
- W4385989288 created "2023-08-19" @default.
- W4385989288 creator A5000553093 @default.
- W4385989288 creator A5003348942 @default.
- W4385989288 creator A5009352804 @default.
- W4385989288 creator A5013557141 @default.
- W4385989288 creator A5018801529 @default.
- W4385989288 creator A5026014632 @default.
- W4385989288 creator A5039952665 @default.
- W4385989288 creator A5047416220 @default.
- W4385989288 creator A5079452824 @default.
- W4385989288 date "2023-08-01" @default.
- W4385989288 modified "2023-09-23" @default.
- W4385989288 title "TIPS-21 PHASE I/II STUDY OF STEREOTACTIC RADIOSURGERY WITH CONCURRENT OLAPARIB FOLLOWED BY ADJUVANT DURVALUMAB AND PHYSICIAN’S CHOICE SYSTEMIC THERAPY IN SUBJECTS WITH BREAST CANCER BRAIN METASTASES (SOLARA)" @default.
- W4385989288 doi "https://doi.org/10.1093/noajnl/vdad070.151" @default.
- W4385989288 hasPublicationYear "2023" @default.
- W4385989288 type Work @default.
- W4385989288 citedByCount "0" @default.
- W4385989288 crossrefType "journal-article" @default.
- W4385989288 hasAuthorship W4385989288A5000553093 @default.
- W4385989288 hasAuthorship W4385989288A5003348942 @default.
- W4385989288 hasAuthorship W4385989288A5009352804 @default.
- W4385989288 hasAuthorship W4385989288A5013557141 @default.
- W4385989288 hasAuthorship W4385989288A5018801529 @default.
- W4385989288 hasAuthorship W4385989288A5026014632 @default.
- W4385989288 hasAuthorship W4385989288A5039952665 @default.
- W4385989288 hasAuthorship W4385989288A5047416220 @default.
- W4385989288 hasAuthorship W4385989288A5079452824 @default.
- W4385989288 hasBestOaLocation W43859892881 @default.
- W4385989288 hasConcept C104317684 @default.
- W4385989288 hasConcept C121608353 @default.
- W4385989288 hasConcept C126322002 @default.
- W4385989288 hasConcept C143998085 @default.
- W4385989288 hasConcept C182979987 @default.
- W4385989288 hasConcept C185592680 @default.
- W4385989288 hasConcept C2778164965 @default.
- W4385989288 hasConcept C2779013556 @default.
- W4385989288 hasConcept C2779138821 @default.
- W4385989288 hasConcept C2779962180 @default.
- W4385989288 hasConcept C2780387249 @default.
- W4385989288 hasConcept C509974204 @default.
- W4385989288 hasConcept C530470458 @default.
- W4385989288 hasConcept C55493867 @default.
- W4385989288 hasConcept C71924100 @default.
- W4385989288 hasConcept C82381507 @default.
- W4385989288 hasConceptScore W4385989288C104317684 @default.
- W4385989288 hasConceptScore W4385989288C121608353 @default.
- W4385989288 hasConceptScore W4385989288C126322002 @default.
- W4385989288 hasConceptScore W4385989288C143998085 @default.
- W4385989288 hasConceptScore W4385989288C182979987 @default.
- W4385989288 hasConceptScore W4385989288C185592680 @default.
- W4385989288 hasConceptScore W4385989288C2778164965 @default.
- W4385989288 hasConceptScore W4385989288C2779013556 @default.
- W4385989288 hasConceptScore W4385989288C2779138821 @default.
- W4385989288 hasConceptScore W4385989288C2779962180 @default.
- W4385989288 hasConceptScore W4385989288C2780387249 @default.
- W4385989288 hasConceptScore W4385989288C509974204 @default.
- W4385989288 hasConceptScore W4385989288C530470458 @default.
- W4385989288 hasConceptScore W4385989288C55493867 @default.
- W4385989288 hasConceptScore W4385989288C71924100 @default.
- W4385989288 hasConceptScore W4385989288C82381507 @default.
- W4385989288 hasIssue "Supplement_3" @default.
- W4385989288 hasLocation W43859892881 @default.
- W4385989288 hasOpenAccess W4385989288 @default.
- W4385989288 hasPrimaryLocation W43859892881 @default.
- W4385989288 hasRelatedWork W1975187426 @default.
- W4385989288 hasRelatedWork W2283853409 @default.
- W4385989288 hasRelatedWork W2312629880 @default.
- W4385989288 hasRelatedWork W2388910868 @default.
- W4385989288 hasRelatedWork W2887088455 @default.
- W4385989288 hasRelatedWork W2979476567 @default.
- W4385989288 hasRelatedWork W3164611713 @default.
- W4385989288 hasRelatedWork W4210532624 @default.
- W4385989288 hasRelatedWork W4283022593 @default.
- W4385989288 hasRelatedWork W59211302 @default.
- W4385989288 hasVolume "5" @default.
- W4385989288 isParatext "false" @default.
- W4385989288 isRetracted "false" @default.
- W4385989288 workType "article" @default.